– Senior Members of the US Government Visit One of Amneal’s 12 Manufacturing Sites
BRIDGEWATER, N.J. – (BUSINESS WIRE) – Amneal Pharmaceuticals, Inc. (NYSE: AMRX ) (“Amneal” or the “Company”) announced today that the U.S. Department of Health and Human Services (HHS) ) delegation and US Food and Drug Administration (FDA) and local government officials recently visited the company’s manufacturing facility in Matoda, India. The visit follows the G20 health ministers meeting in Gandhinagar, India, on August 18-19, where health ministers from around the world gathered to discuss global health issues.
The delegation included Ms. Loyce Pace, Assistant Secretary for Global Affairs, HHS Head for Global Priorities and Policy, HHS India Health Ms. Genessa Giorgi, Commissioner; Dr. Sarah McMullen, Health Commissioner, HHS India; and Dr. HG Koshia, Country Director, FDA India, and Commissioner, Food and Drug Control Authority of India (FDCA), Gujarat, India. A tour of the Amneal facility demonstrates the company’s advanced automation and complex medical capabilities, the general complexity of drug manufacturing, and the importance of investing in technologies that ensure a safe and effective drug supply. Amneal’s plant in Matoda is one of the company’s 12 pharmaceutical plants.
“Amneal is a global pharmaceutical company committed to providing affordable access to essential medicines. Across our large and diverse portfolio, we deliver key therapies to meet the needs of patients. We are honored to be part of this important visit, Share our role in delivering safe and effective medicines around the world. We look forward to continuing our work to address critical issues affecting the U.S. pharmaceutical industry’s ability to serve patients, including shortages,” said Co-CEOs Chirag and Chintu Patel .
Amneal Pharmaceuticals, Inc. (NYSE: AMRX ), headquartered in Bridgewater, New Jersey, is a fully integrated global pharmaceutical company. We develop, manufacture and distribute a diverse portfolio of approximately 270 pharmaceuticals, primarily in the United States, that make wellness possible. In generics, the company is expanding into a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its areas of specialty, Amneal has a growing portfolio of branded medicines primarily focused on central nervous system and endocrine disorders, as well as a pipeline focused on unmet needs. Through its AvKARE segment, the company is a distributor of pharmaceutical and other products for the US federal government, retail and institutional markets. For more information, please visit www.amneal.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements contained herein that are not historical facts may be forward-looking statements (as defined in the United States Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements about management’s intentions, plans, beliefs, expectations, financial performance or future projections, including: discussions of future operations, including international expansion; expected or estimated operating and financial results; The company’s growth prospects and opportunities and growth strategy; product development and launch; successful commercialization and market acceptance of new products and other non-historical statements. Words such as “plan,” “anticipate,” “will,” “anticipate,” “estimate,” or similar words or their negatives, are intended to identify estimates and forward-looking statements.
Readers are cautioned not to rely on these forward-looking statements. These forward-looking statements are based on current expectations about future events, including expectations about future market conditions, company performance and financial results, operating investments, business prospects, new strategies and growth plans, the competitive environment and other events. Should underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could differ materially from the company’s expectations and projections.
These risks and uncertainties include, but are not limited to: our ability to successfully develop, license, acquire and commercialize new products in a timely manner; the competition we face in the pharmaceutical industry from branded and generic pharmaceutical companies and the impact of such competition on our pricing power; Impact; our ability to obtain exclusive marketing rights to our products; our ability to manage growth through acquisitions or otherwise; our revenue derived from the sale of a limited number of products, a significant portion of which is through a limited number of customers; certain customer segments our reliance on third-party suppliers and distributors for raw materials for our products and certain finished goods; our substantial debt and our ability to generate sufficient cash to service future debt, and the impact of interest rate fluctuations on such debt Impact; our ability to obtain satisfactory terms in negotiating refinancing or other new debt; reliance on third-party agreements for some of our products; legal, regulatory actions taken by our branded competitors to prevent competition from our generic alternatives and legislative measures; risks associated with federally regulated arrangements between manufacturers of branded products and generic products; our reliance on licensing certain proprietary technologies from time to time; our expenditure of substantial resources on research and development; product liability risks and consumer and other Risk of other claims against us by third parties; Risks related to changes in the regulatory environment, including U.S. federal and state laws related to healthcare fraud abuse, health information privacy and security and changes in such laws; Food and Drug Administration changes in product approval requirements; the impact of healthcare reform and changes in coverage and reimbursement levels by government authorities and other third-party payers; our potential expansion into other international markets exposes us to additional regulatory, economic, social and political uncertainty; Certainty, including recent events affecting the financial services industry; our ability to identify, make and integrate acquisitions or investments in complementary businesses and products on favorable terms; the impact of global economic, political or other catastrophic events; our ability to attract, hire and retain our ability to retain highly skilled personnel; our obligations under tax receivable agreements may be substantial; our Class A common stock ownership is highly concentrated and we are controlled by the Amneal Group. Forward-looking statements contained herein are also generally subject to other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission from time to time, including the Company’s most recent Annual Report, Item 1A “Risk Factors” on Form 10-K and its subsequent Reported on Forms 10-Q and 8-K. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. The forward-looking statements contained herein speak only as of the date hereof, and we undertake no obligation to revise or update such statements to reflect events or circumstances occurring after the date hereof.
Head of Investor Relations
Content provided by Business Wire. Jinri Toutiao is not responsible for the content provided or any link related to the content. Toutiao is not responsible for the correctness, topicality or quality of the content.